Institute of Psychiatry, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo
São Paulo, 05403-010, Brazil
NCT Number: NCT03068429
24 OCD patients and 24 healthy subjects will be submitted to a two-day fear conditioning paradigm during acquisition of functional magnetic resonance imaging (fMRI). OCD patients will be submitted to the paradigm at two timepoints: baseline and 4 weeks after treatment initiation with sertraline up to 200mg/day or maximum tolerated dosage. OCD patients are expected to demonstrate worsened extinction retention compared to healthy subjects at baseline. Sertraline treatment is expected to improve extinction retention compared to baseline and to normalize the brain regions being recruited with the conditioned stimuli presented during the recall phase.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
São Paulo, 05403-010, Brazil
Fear conditioning paradigms are used to investigate the learning process of the fear response in patients with psychiatric disorders and healthy subjects. Patients with post traumatic stress disorder have been shown to fail to retrieve the memory of fear extinction during the recall phase of the fear conditioning paradigm when compared to healthy subjects. In one previous trial, obsessive-compulsive disorder (OCD) patients have demonstrated the same failure to recall extinction and the results from functional magnetic resonance imaging (fMRI) activation maps have shown different regions being recruited during recall when compared with healthy subjects. However, in that previous trial, some of the OCD patients included were already taking medication for OCD. In the current trial, we will evaluate 24 unmedicated OCD patients with a two-day fear conditioning paradigm before and after 4-weeks of treatment initiation with sertraline up to 200mg/day or maximum tolerated dosage. Sertraline is a first-line treatment option for OCD. At baseline, OCD patients will be compared to 24 healthy subjects. At post treatment, fear conditioning and fMRI results wil be compared to baseline. OCD patients are expected to demonstrate worsened extinction retention compared to healthy subjects at baseline. Sertraline treatment is expected to improve extinction retention compared to baseline and to normalize the brain regions being recruited with the conditioned stimuli presented during the recall phase. By "normalize" we mean that after treatment the regions being recruited will be the same as the ones recruited by healthy subjects during baseline, in other words, differences found at baseline regarding brain activation by the conditioned stimuli are expected to disappear after treatment.
Abbreviations: CS= conditioned stimuli, CS+= conditioned stimuli to shock, CS-=neutral conditioned stimuli, CS+E= extinguished conditioned stimuli to shock, CS+U=unextinguished conditioned stimuli to shock
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy controls
-willingness to participate in research
OCD patients
Exclusion criteria
Healthy controls
OCD patients
first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
Other names: sertraline 50mg, zoloft
Time frame: Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
Equation: 100-((MEAN(2 first CS+E during recall)/MAXIMUM(2 last CS+E during extinction))*100)
Time frame: Baseline for both groups (OCD and helthy subjects), change from baseline to 4 weeks after treatment initiation only for intervention group
ventro medial prefrontal cortex (vmPFC) activation during recall phase
Time frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
Yale Brown Obsessive Compulsive Scale reduction (final score minus initial score)
Time frame: Baseline
Equation: 100-((MEAN(2 first CS+E during recall)/MAXIMUM(2 last CS+E during extinction))*100)
Time frame: Baseline (all subjects)
ventro medial prefrontal cortex (vmPFC) activation during recall phase
Time frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
Equation: MEAN(all CS+ during conditioning)-MEAN(all CS- during conditioning)
Time frame: Baseline (all subjects)
Equation: MEAN(all CS+ during conditioning)-MEAN(all CS- during conditioning)
Time frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
Equation: MEAN(first two CS+U during renewal)-MEAN(first two CS+U during recall)
Time frame: Baseline (all subjects)
Equation: MEAN(first two CS+U during renewal)-MEAN(first two CS+U during recall)
Time frame: Change from baseline to 4 weeks after treatment initiation (only interventional group)
Gain in amygdala activation during conditioning for CS+ presentations
Time frame: Baseline (all subjects)
Gain in amygdala activation during conditioning for CS+ presentations
Time frame: Baseline (all subjects)
Alternative activations (OCD patients versus controls), regions other than the vmPFC, activated with CS+ presentations during recall
Time frame: Change between baseline and 4 weeks after treatment initiation (only interventional group)
Alternative activations (OCD patients post treatment compared with baseline), regions other than the vmPFC, activated with CS+E presentations during recall
University of Sao Paulo
Other
Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline.
Acronym: FEARCON
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05552014
Anxiety Disorders, Mental Disorders
Hefei, Anhui, China
View Trial DetailsNCT04967560
Anxiety Disorders, Mental Disorders
Zhengzhou, Henan, China
View Trial DetailsNCT05503017
Anxiety Disorders, Generalized Anxiety Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT04693351
Anxiety Disorders, Mental Disorders
Phoenix, Arizona, United States
View Trial Details